The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...
Fintel reports that on October 23, 2025, Citigroup maintained coverage of Moderna (NasdaqGS:MRNA) with a Neutral ...
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...
Barchart on MSN
Moderna Earnings Preview: What to Expect
Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.
Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...
Multiple analysts have issued price targets for $MRNA recently. We have seen 10 analysts offer price targets for $MRNA in the last 6 months, with a median target of ...
Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...
Moderna (MRNA) has drawn attention after its stock climbed around 12% over the past week. Investors are weighing the ...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the October 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback